ZVRA Q3 2025 Earnings — Zevra Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ZVRAZevra Therapeutics, Inc.

$618M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$26M+605.4% YoY

Gross Profit

$25M94.0% margin

Operating Income

$4M15.9% margin

Net Income

-$544,000-2.1% margin

EPS (Diluted)

$-0.01

QoQ Revenue Growth

+0.7%

Cash Flow

Operating Cash Flow

$5M

Free Cash Flow

$4M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$270M

Total Liabilities

$137M

Stockholders' Equity

$133M

Cash & Equivalents

$54M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$26M	$4M	+605.4%
Gross Profit	$25M	$1M	+1660.8%
Operating Income	$4M	-$27M	+115.2%
Net Income	-$544,000	-$33M	+98.4%